Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MPX Marine Products Corp

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-2.10 (-2.59%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 522,352 shares is on pace to be much greater than NVS's 10-day average volume of 1,640,966 shares.


UPDATE: Pfizer CEO: Coronavirus vaccine could be distributed in U.S. by end of year

8:40 am ET September 14, 2020 (MarketWatch)

By Mike Murphy

Drug manufacturer could know if vaccine is effective by end of October, says Albert Bourla

The chief executive of Pfizer Inc. said Sunday that the pharmaceutical giant should know if its experimental COVID-19 vaccine works by the end of October -- and, if approved, it could be distributed in the U.S. by the end of the year.

In an interview on Sunday ( with CBS News' "Face the Nation," CEO Albert Bourla said there is a "good chance" of getting key data from late-stage trials to the Food and Drug Administration by the end of October, and that the company is already producing the vaccine, just in case.

"We started already manufacturing, and we have already manufactured hundreds of thousands of doses, so just in case we have a good study readout, conclusive, and FDA, plus the advisory committee, feels comfortable, that we will be ready," Bourla said.

Read:Here's what you need to know about clinical trials as drug makers push forward with coronavirus vaccine studies (

He said Pfizer (PFE), which is teaming with German drug maker BioNTech (BNTX) on the coronavirus vaccine's development, will absorb a financial hit if the vaccine fails, but was adamant about not taking government funding to keep the process apolitical, with CEOs of nine pharmaceutical companies having recently felt compelled to push back against a growing perception that Donald Trump and his administration were pressuring regulators to get vaccines and therapies to market ahead of the Nov. 3 presidential election, pledging that their companies would not seek premature approvals or authorizations (

Bourla said Pfizer has already invested about $1.5 billion into the vaccine effort. "At the end of the day, it's only money. But that will not break the company, although it's going to be painful," he said of the possibility that the vaccine does not prove to be effective.

On Saturday, Pfizer and BioNTech sought FDA approval to expand their Phase 3 vaccine trial ( to up to 44,000 participants, up from the originally planned 30,000.

In July, the companies announced a $1.95 billion deal with the U.S. government ( to produce 100 million doses of the vaccine, if it wins approval by regulators.

The vaccine effort by Pfizer and BioNTech is one of many currently underway ( On Saturday, AstraZeneca PLC (AZN.LN) said it has resumed its vaccine study in the U.K ( after halting global studies last week to investigate an unexplained illness in a participant. While British regulators said the trial was safe to proceed, the study remains paused in other countries.

-Mike Murphy; 415-439-6400;

(END) Dow Jones Newswires

September 14, 2020 08:40 ET (12:40 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.